Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NeoStem’s Subsidiary, PCT Enters into Services Agreement with Adaptimmune

Published: Thursday, January 24, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.

NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), have announced a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune’s clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).

PCT’s services will include the transfer and qualification of Adaptimmune’s manufacturing process for its NYESO-1c259-T cell therapy product candidate at PCT’s facility in Allendale, New Jersey and subsequent manufacturing of the product for Adaptimmune’s clinical trials.

Adaptimmune develops products containing unique engineered T cell receptors for the treatment of cancer and infectious diseases. The company has a research base in Oxford, UK and a clinical base in Philadelphia, Pennsylvania.

In December, at the American Society of Hematology conference, Adaptimmune has announced encouraging preliminary results from its expanded multiple myeloma trial. Related trials in melanoma and sarcoma are also recruiting patients.

PCT is an internationally recognized contract development and manufacturing organization with facilities in Allendale, New Jersey and Mountain View, California.

The company has expertise in GMP manufacture for cell therapies, including dendritic cells, stem cells and T cells.

Notably, PCT provided manufacturing for the pivotal studies for Dendreon’s Provenge®, the first cell therapy approved for cancer treatment.

“With our sights set on future pivotal trials for our T cell therapy products, we have invested significant effort towards establishing capabilities within Adaptimmune that support expansion of our clinical platform in terms of both scale and compliance with FDA requirements beyond phase I/II. Our relationship with PCT is an important component,” said James Noble, Chief Executive Officer of Adaptimmune.

Noble continued, “PCT’s impressive level of experience in the burgeoning field of cell therapy, combined with their flexible capacity and professionalism, are among the reasons we selected them for this critical role for our T cell product.”

“We are excited to enter into this agreement with Adaptimmune, an innovator for T cell therapy to treat cancers,” said Robert A. Preti, PhD, President and Chief Scientific Officer of PCT.

Preti continued, “Given our extensive experience with technology transfer, process qualification and GMP manufacturing, we feel PCT will be an asset to Adaptimmune as it develops its product for the U.S. commercial market.”

Dr. Robin L. Smith, NeoStem’s Chairman and Chief Executive Officer, stated that, “PCT’s expertise is recognized globally as demonstrated by the services agreement executed with Adaptimmune. As PCT continues to expand its GMP manufacturing capabilities and focus to support the development of an increasingly wide range of cell therapies under development, it remains focused on providing outstanding client services.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Tuesday, July 21, 2015
Adaptimmune Secures $104 Million in Series A Financing
Company will use funding to advance programmes in multiple cancer indications.
Friday, September 26, 2014
Adaptimmune Announces Full-time Appointment of James Noble as CEO
Appointment will become effective from 31st March.
Thursday, March 27, 2014
Adaptimmune Awarded £2.1m from the Biomedical Catalyst Fund
The prestigious award supports Adaptimmune’s clinical pipeline expansion.
Tuesday, March 25, 2014
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells
Study continues to report encouraging response rates, safety and proof of mechanism.
Thursday, December 12, 2013
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial
Adaptimmune announced that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer.
Thursday, July 25, 2013
Adaptimmune Announces Preliminary Results from an Early Phase Trial of Gene Engineered T Cells
Study reports encouraging response rates, and data support safety and preliminary proof of mechanism.
Tuesday, December 11, 2012
Investigators to Present Preliminary Findings for Adaptimmune’s Gene Engineered T Cells in Myeloma
Presentation of data at the annual ASH meeting on Monday 10 December.
Monday, November 19, 2012
Adaptimmune Announces New Board Appointments
Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director both with immediate effect.
Monday, September 26, 2011
Adaptimmune Announces New Board Appointments as Clinical Programmes Get Underway
Company prepares to open trials in further cancer indications in 2012.
Thursday, September 22, 2011
Adaptimmune Announces Opening of Phase I/II Clinical Trial for Metastatic Melanoma
The Phase I/II, two cohort, open label clinical trial in metastatic melanoma opens at Washington University, St. Louis, Missouri.
Monday, June 20, 2011
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!